Related Experiment Video
Updated: Aug 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Homozygous familial hypercholesterolemia. Response to combined cholestyramine and lovastatin therapy]
I Obando Santaella1, E Fernández Gómez, I Mongil Ruiz
1Servicio de Pediatría, Hospital G B de Pozoblanco, Córdoba.
Insights
Homozygous familial hypercholesterolemia (FH) is a severe genetic disorder. A combination therapy of lovastatin and cholestyramine effectively reduced cholesterol levels by 67% in a patient with FH.
Area of Science:
- Cardiology
- Genetics
- Biochemistry
Background:
- Familial hypercholesterolemia (FH) is an inherited disorder characterized by high levels of low-density lipoprotein (LDL) cholesterol.
- Homozygous FH results from genetic defects in the LDL receptor, leading to severe hypercholesterolemia and premature cardiovascular disease.
- Standard drug therapies are often ineffective in patients with homozygous FH.
Observation:
- A patient with receptor-defective homozygous FH was treated with a combination regimen.
- The treatment involved lovastatin and cholestyramine.
- A 7-month follow-up period was conducted.
Findings:
- The combined drug regimen resulted in a significant reduction in cholesterol levels by 67%.
- Adverse events related to the treatment were observed during the follow-up period.
Implications:
- Combined drug therapy may be a promising treatment option for patients with homozygous FH, particularly those with residual receptor activity.
- Further research is needed to optimize treatment strategies and manage adverse events in homozygous FH.
- This case highlights the potential of combination therapy in managing severe genetic lipid disorders.
Abstract:
Homozygous familiar hypercholesterolemia (FH) is a serious inherited disease caused by a genetic defect in the cell surface receptor that controls the degradation of low density lipoprotein (LDL). These patients often have myocardial infarction in their teens or early adulthood and are usually unresponsive to drugs. Recently it has been reported promising results using combined drugs regimens in patients with residual receptor activity. We report a new additional patient with receptor-defective homozygous FH treated with a combination of lovastatin and cholestyramine. The cholesterol levels were reduced in a 67% and there were adverse events related to treatment during a 7 month period of follow-up.
More Related Videos
Related Concept Videos
Lipid Digestion
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cholesterol: Significance and Regulation
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management
Lipid Catabolism

